Vertex's Kalydeco Gets FDA Nod for Cystic Fibrosis in Infants

Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has approved its cystic fibrosis (CF) drug Kalydeco (ivacaftor) for an expanded use in infants aged between four and less than six months with at least one mutation in their CFTR gene that is responsive to Kalydeco.